Screener
Enliven Therapeutics ELVN Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income (expense), net | ||
| Interest income | 4,196 | 3,196 |
| Other expense | — | (47) |
| Total other income (expense), net | 4,196 | 3,149 |
| Net loss | (23,627) | (28,544) |
| Other comprehensive income (loss): | ||
| Net unrealized losses on marketable securities | (716) | (71) |
| Comprehensive loss | $(24,343) | $(28,615) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's other income (expense)?
- Enliven Therapeutics (ELVN) reported other income (expense) of $4.2M in Q1 2026.
- How has Enliven Therapeutics's other income (expense) changed year-over-year?
- Enliven Therapeutics's other income (expense) increased by 33.2% year-over-year, from $3.15M to $4.2M.
- What is the long-term trend for Enliven Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Enliven Therapeutics's other income (expense) has grown at a 307.3% compound annual growth rate (CAGR), from $58K to $15.96M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Enliven Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude